Sign in with Google. Opens in new tab
bearish
Changchun High & New Tech (000661.CH) - Logic Change?
235 Views16 Aug 2021 01:08
The article analyzed Changchun High & New Tech in terms of its 2021/1H financial results,media exposure of growth hormone abuse, possibility of volume-based purchase on growth hormone and the outlook.
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 4-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Fengxiang (9977 HK): Precondition Satisfied
- Shin Kong/Taishin Merger Flows and Perhaps Unforeseen Problems
- Curator's Cut: CC Vs DD, Singapore’s IPO Momentum and Pair Trade Ideas Galore
- A/H Premium Tracker (To 4 July 2025): "Beautiful Skew" Continues as SB Buys Wide Spread Hs
- Merger Arb Mondays (07 Jul) - Seven & I, Shibaura, Insignia, New World, ENN Energy, HKBN, Fengxiang
Top Unpaywalled Insights
More »- Curator's Cut: CC Vs DD, Singapore’s IPO Momentum and Pair Trade Ideas Galore
- [IO Technicals 2025/27] Bullish Momentum Gains Traction
- Oversupply Meets Tepid Demand Weighing Down on Soybean Meal
- [IO Technicals 2025/26] Bearish Momentum Intensifies
- "The Data Bottleneck in Quant Finance — and How to Break It" With David Forino, CTO of Quanted
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Shanghai MicroPort MedBot Group (2252.HK) - Optimistic About the Outlook08 Feb 2022
- Anke Biotechnology (300009CH) Vs Changchun High & New Tech (000661CH)-Growth Hormone VBP and Outlook03 Feb 2022
- Pre-IPO CANbridge Pharmaceuticals - Insights on Products, Pipeline and the Concerns17 Aug 2021
- Changchun High & New Tech (000661.CH) - Logic Change?16 Aug 2021
- Changchun High & New Tech (000661.CH) - Insights on Recent Pullback & The Future Business Outlook27 May 2021
- Pre-IPO Shanghai HeartCare Medical Technology - Promising Market but Fierce Competition31 Mar 2021
- I-Mab (IMAB US) - Insights On Core Products TJC4, TJ202 and TJ10129 Mar 2021
x